Haleon (LON:HLN) Given New GBX 447 Price Target at Berenberg Bank

Haleon (LON:HLN) had its price target boosted by Berenberg Bank from GBX 410 ($5.24) to GBX 447 ($5.71) in a research report sent to investors on Monday, Marketbeat reports. They currently have a buy rating on the stock.

A number of other equities analysts have also issued reports on the company. Barclays reduced their target price on Haleon from GBX 390 ($4.98) to GBX 383 ($4.89) and set an overweight rating for the company in a research note on Tuesday, April 9th. HSBC initiated coverage on Haleon in a report on Thursday, April 18th. They issued a buy rating on the stock.

Haleon Trading Down 0.1 %

LON HLN opened at GBX 373.60 ($4.77) on Monday. Haleon has a 12-month low of GBX 308.37 ($3.94) and a 12-month high of GBX 375.24 ($4.80). The company has a fifty day simple moving average of GBX 335.98 and a two-hundred day simple moving average of GBX 329.20. The company has a current ratio of 1.04, a quick ratio of 0.93 and a debt-to-equity ratio of 57.42. The stock has a market cap of £34.11 billion and a P/E ratio of 3,113.33.

Haleon Cuts Dividend

The business also recently disclosed a dividend, which will be paid on Thursday, September 19th. Shareholders of record on Thursday, August 15th will be paid a dividend of GBX 2 ($0.03) per share. The ex-dividend date of this dividend is Thursday, August 15th. This represents a dividend yield of 0.57%. Haleon’s payout ratio is currently 5,000.00%.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.